These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. METTL3-mediated HPV vaccine enhances the effect of anti PD-1 immunotherapy to alleviate the development of cutaneous squamous cell carcinoma. Zhang Y; Wang Y; Guo S; Cui H An Bras Dermatol; 2024; 99(2):210-222. PubMed ID: 38030537 [TBL] [Abstract][Full Text] [Related]
71. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240 [TBL] [Abstract][Full Text] [Related]
72. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682 [TBL] [Abstract][Full Text] [Related]
74. Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. Shalhout SZ; Park JC; Emerick KS; Sullivan RJ; Kaufman HL; Miller DM J Am Acad Dermatol; 2021 Oct; 85(4):1038-1040. PubMed ID: 33476726 [No Abstract] [Full Text] [Related]
75. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma. Corbett M; Tohani S; Ramli R; O'Duffy F JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669 [TBL] [Abstract][Full Text] [Related]
76. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients. Hanania HL; Lewis DJ J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250 [TBL] [Abstract][Full Text] [Related]
77. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143 [TBL] [Abstract][Full Text] [Related]
78. Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2. Ma WL; Chou CH; Chen JP; Kuo SH Dermatol Ther; 2020 Nov; 33(6):e14035. PubMed ID: 32683791 [TBL] [Abstract][Full Text] [Related]
79. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900 [TBL] [Abstract][Full Text] [Related]
80. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy. Day F; Kumar M; Fenton L; Gedye C J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]